cbdMD, Inc.
YCBD · AMEX
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.05 | 0.01 | -0.01 |
| FCF Yield | -3,783.80% | -3.96% | -27.60% | -14.55% |
| EV / EBITDA | 0.00 | -10.06 | -0.93 | -6.83 |
| Quality | ||||
| ROIC | 0.00% | -98.64% | -72.38% | 97.58% |
| Gross Margin | 0.00% | 61.57% | 62.01% | 63.09% |
| Cash Conversion Ratio | – | 0.10 | 0.19 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -18.05% | -18.41% | -5.45% |
| Free Cash Flow Growth | -28,551.21% | 86.02% | 70.62% | 4.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.79 | -0.09 | 0.12 |
| Interest Coverage | 0.00 | -108.10 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 3.17 | 2.26 | 3.07 |
| Cash Conversion Cycle | 0.00 | 58.61 | 103.75 | 76.92 |